HR
VKTX icon

Hayden Royal’s Viking Therapeutics VKTX Stock Holding History

Hayden Royal’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-16,900
Closed -$101K – 201
2021
Q2 		$101K Hold
16,900
– – 0.06% 202
2021
Q1 		$107K Buy
+16,900
New +$119K 0.06% 198
2020
Q4 		– Sell
-19,675
Closed -$114K – 569
2020
Q3 		$114K Sell
19,675
-458
-2% -$3.15K 0.06% 192
2020
Q2 		$145K Sell
20,133
-875
-4% -$5.81K 0.08% 155
2020
Q1 		$98.3K Buy
+21,008
New +$129K 0.06% 211
2019
Q4 		– Sell
-18,078
Closed -$124K – 248
2019
Q3 		$124K Buy
18,078
+4,500
+33% +$33.4K 0.11% 157
2019
Q2 		$111K Buy
+13,578
New +$116K 0.12% 151

Other funds holding VKTX

ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Fiera Capital (Canada)
Fiera Capital (Canada) Montreal, Quebec, Canada $29.2B AUM 20.16% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Hayden Royal's VKTX Position: Q3 2021 in Review

Hayden Royal sold out of Viking Therapeutics (VKTX) in Q3 2021, closing a stake of 16,900 shares — an estimated $101K sold.

Hayden Royal first reported a position in VKTX in Q2 2019 and held it in 7 quarters. The position peaked at $145K in Q2 2020. 134 funds tracked by Wall St. Rank hold VKTX as of Q3 2021.

  • Hayden Royal reported no remaining Viking Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Hayden Royal sold 16,900 Viking Therapeutics shares in Q3 2021, an estimated $101K.
  • Hayden Royal first reported a position in Viking Therapeutics in Q2 2019 and held it in 7 quarters.
  • Hayden Royal's Viking Therapeutics position peaked at $145K in Q2 2020.
  • 134 funds tracked by Wall St. Rank held Viking Therapeutics as of Q3 2021.

Based on Hayden Royal's 13F filing for Q3 2021, filed 15 Nov 2021.